Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.21 |
52 Week High | US$10.97 |
52 Week Low | US$10.18 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | -1.83% |
1 Year Change | -3.29% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -9.41% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
BIOTM | GB Capital Markets | GB Market | |
---|---|---|---|
7D | 0% | -0.3% | -0.8% |
1Y | -3.3% | 9.4% | 5.8% |
Return vs Industry: BIOTM underperformed the UK Capital Markets industry which returned 9.6% over the past year.
Return vs Market: BIOTM matched the UK Market which returned -2.4% over the past year.
Price Volatility
BIOTM volatility | |
---|---|
BIOTM Average Weekly Movement | n/a |
Capital Markets Industry Average Movement | 4.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BIOTM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOTM's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | fundcentres.lgim.com/uk/private/fund-centre/ETF/Pharma-Breakthrough |
Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF Fundamentals Summary
BIOTM fundamental statistics | |
---|---|
Market cap | n/a |
Earnings (TTM) | €0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BIOTM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOTM income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €0 |
Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did BIOTM perform over the long term?
See historical performance and comparison